Such analyses will reveal tumor cell hierarchies at the genomic and non-genomic level, including the presence of CSCs and the diversities within the tumor microenvironment at a given time (Figure 2).80 In addition, longitudinal sampling from each patient including prior and post treatment can be implemented.44 This approach improves our understanding of the PLC evolution during tumor progression. The gene discussed is HSPG2; the disease is neoplasm.